Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

21. Kisqali for Advanced or Metastatic Breast Cancer – Details

Kisqali for Advanced or Metastatic Breast Cancer – Details Kisqali for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Kisqali for Advanced or Metastatic Breast Cancer – Details Kisqali for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10194 Brand Name Kisqali Generic Name Ribociclib Tumour Type Breast Indication Advanced or Metastatic Breast Cancer Funding Request In combination with an aromatase inhibitor (AI) and a luteinizing (...) hormone releasing hormone (LHRH) agonist for the treatment of pre/peri- menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Novartis Pharmaceuticals Canada Inc. Sponsor Novartis Pharmaceuticals Canada Inc. Submission Date August 26, 2019 Submission Deemed Complete September 10, 2019 Submission Type

2019 CADTH - Pan Canadian Oncology Drug Review

22. Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details

Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details | CADTH.ca Find the information you need Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Project Number pCODR 10171 Brand Name Tecentriq Generic Name Atezolizumab Strength 840 mg (...) /14 mL & 1200 mg/20 mL Tumour Type Breast Indication Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Funding Request In combination with nab-paclitaxel for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1, and who have not received prior chemotherapy for metastatic disease. Maintenance TECENTRIQ should be continued until disease progression or unacceptable toxicity. Review Status Open

2019 CADTH - Pan Canadian Oncology Drug Review

23. Nerlynx for Hormone Receptor-Positive Breast Cancer – Details

Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Nerlynx for Hormone Receptor-Positive Breast Cancer – Details | CADTH.ca Find the information you need Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Project Number pCODR 10172 Brand Name Nerlynx Generic Name Neratinib Strength 40 mg Tumour Type Breast Indication Hormone Receptor-Positive Breast Cancer Funding Request For patients with HER2-positive, hormone (...) receptor-positive breast (HR-positive) cancer who have completed adjuvant trastuzumab-based therapy within the past 12 months Review Status Open for Feedback on Recommendation Pre Noc Submission Yes NOC Date July 16, 2019 Manufacturer Knight Therapeutics Inc. Sponsor Knight Therapeutics Inc. Submission Date April 18, 2019 Submission Deemed Complete May 3, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ May 3, 2019 Check-point meeting July 4, 2019 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

24. Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details

Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10150 Brand Name Ibrance (with Faslodex) Generic Name Palbociclib (with Fulvestrant) Strength 75 mg, 100 mg & 125 mg Tumour Type Breast (...) Indication Advanced or Metastatic Breast Cancer Funding Request In combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy, Pre- or perimenopausal women must also be treated with a luteinizing hormone releasing hormone (LHRH) agonist Review Status Notification to Implement Issued Pre Noc Submission No NOC Date May

2019 CADTH - Pan Canadian Oncology Drug Review

25. Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details

Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details | CADTH.ca Find the information you need Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Project Number pCODR 10169 (...) Brand Name Ogivri Generic Name Trastuzumab Strength 150 mg/vial and 440 mg/vial Tumour Type Breast / Gastrointestinal Indication Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar Funding Request For the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel

2019 CADTH - Pan Canadian Oncology Drug Review

26. Trastuzumab for Breast and Gastric Cancer Biosimilar – Details

Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Trastuzumab for Breast and Gastric Cancer Biosimilar – Details | CADTH.ca Find the information you need Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Project Number pCODR 10160 Brand Name TBD Generic Name Trastuzumab Strength Tumour Type Breast & Gastrointestinal Indication Breast and Gastric Cancer Biosimilar Funding Request Breast and Gastric Cancer

2019 CADTH - Pan Canadian Oncology Drug Review

27. Abemaciclib for advanced or metastatic Breast Cancer – Details

Abemaciclib for advanced or metastatic Breast Cancer – Details Abemaciclib for advanced or metastatic Breast Cancer – Details | CADTH.ca Find the information you need Abemaciclib for advanced or metastatic Breast Cancer – Details Abemaciclib for advanced or metastatic Breast Cancer – Details Project Number pCODR 10161 Brand Name Verzenio Generic Name Abemaciclib Strength 50 mg, 100 mg, 150 mg and 200 mg Tumour Type Breast Indication Advanced or metastatic breast cancer Funding Request (...) For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer: • In combination with an aromatase inhibitor in postmenopausal women as initial endocrine based therapy. • In combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone agonist. Review Status Notification to Implement Issued Pre Noc Submission Yes

2019 CADTH - Pan Canadian Oncology Drug Review

28. Use of Endocrine Therapy for Breast Cancer Risk Reduction

Use of Endocrine Therapy for Breast Cancer Risk Reduction Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.01472 Journal of Clinical Oncology - published online before print September 3, 2019 PMID: Use of Endocrine Therapy for Breast Cancer Risk Reduction (...) 9 Yale Cancer Center, New Haven, CT 10 Northwestern University Feinberg School of Medicine, Chicago, IL 11 University of Basel Nursing Science, Basel, Switzerland 12 Mayo Clinic Cancer Center, Rochester, MN 13 Cancer Care of Western North Carolina, Asheville, NC 14 Florida International University, Miami, FL 15 American Society of Clinical Oncology, Alexandria, VA Abstract Section: PURPOSE To update the ASCO guideline on pharmacologic interventions for breast cancer risk reduction and provide

2019 American Society of Clinical Oncology Guidelines

29. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. (PubMed)

Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Published findings on breast cancer risk associated with different types of menopausal hormone therapy (MHT) are inconsistent, with limited information on long-term effects. We bring together the epidemiological evidence, published and unpublished, on these associations, and review the relevant randomised evidence.Principal analyses used (...) never users.During prospective follow-up, 108 647 postmenopausal women developed breast cancer at mean age 65 years (SD 7); 55 575 (51%) had used MHT. Among women with complete information, mean MHT duration was 10 years (SD 6) in current users and 7 years (SD 6) in past users, and mean age was 50 years (SD 5) at menopause and 50 years (SD 6) at starting MHT. Every MHT type, except vaginal oestrogens, was associated with excess breast cancer risks, which increased steadily with duration of use

2019 Lancet

30. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. (PubMed)

Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Surgery has been used as part of breast cancer treatment for centuries; however any surgical procedure has the potential risk of infection. Infection rates for surgical treatment of breast cancer are documented at between 3% and 15%, higher than average for a clean surgical procedure. Pre- and perioperative antibiotics have been found to be useful in lowering infection rates in other surgical groups, yet (...) there is no consensus on the use of prophylactic antibiotics for breast cancer surgery. This is an update of a Cochrane Review first published in 2005 and last updated in 2014.To determine the effects of prophylactic (pre- or perioperative) antibiotics on the incidence of surgical site infection (SSI) after breast cancer surgery.For this fourth update, in August 2018 we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE (including In-Process

2019 Cochrane

31. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Medications to reduce risk of breast cancer are effective for women at increased risk but also cause adverse effects.To update the 2013 US Preventive Services Task Force systematic review on medications to reduce risk of primary (first diagnosis) invasive breast cancer in women.Cochrane Central Register of Controlled Trials (...) and Database of Systematic Reviews, EMBASE, and MEDLINE (January 1, 2013, to February 1, 2019); manual review of reference lists.Discriminatory accuracy studies of breast cancer risk assessment methods; randomized clinical trials of tamoxifen, raloxifene, and aromatase inhibitors for primary breast cancer prevention; studies of medication adverse effects.Investigators abstracted data on methods, participant characteristics, eligibility criteria, outcome ascertainment, and follow-up. Results of individual

2019 JAMA

32. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. (PubMed)

Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. Breast cancer is the most common nonskin cancer among women in the United States and the second leading cause of cancer death. The median age at diagnosis is 62 years, and an estimated 1 in 8 women will develop breast cancer at some point in their lifetime. African American women are more likely to die of breast cancer compared with women of other races.To update the 2013 US Preventive (...) Services Task Force (USPSTF) recommendation on medications for risk reduction of primary breast cancer.The USPSTF reviewed evidence on the accuracy of risk assessment methods to identify women who could benefit from risk-reducing medications for breast cancer, as well as evidence on the effectiveness, adverse effects, and subgroup variations of these medications. The USPSTF reviewed evidence from randomized trials, observational studies, and diagnostic accuracy studies of risk stratification models

2019 JAMA

33. Taxanes for adjuvant treatment of early breast cancer. (PubMed)

Taxanes for adjuvant treatment of early breast cancer. Adjuvant chemotherapy improves survival in premenopausal and postmenopausal women with early breast cancer. Taxanes are highly active chemotherapy agents used in metastatic breast cancer. Review authors examined their role in early breast cancer. This review is an update of a Cochrane Review first published in 2007.To assess the effects of taxane-containing adjuvant chemotherapy regimens for treatment of women with operable early breast (...) cancer.For this review update, we searched the Specialised Register of the Cochrane Breast Cancer Group, MEDLINE, Embase, CENTRAL (2018, Issue 6), the WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov on 16 July 2018, using key words such as 'early breast cancer' and 'taxanes'. We screened reference lists of other related literature reviews and articles, contacted trial authors, and applied no language restrictions.Randomised trials comparing taxane-containing regimens

2019 Cochrane

34. Breast Cancer: Medication Use to Reduce Risk

Breast Cancer: Medication Use to Reduce Risk Final Recommendation Statement: Breast Cancer: Medication Use to Reduce Risk - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Breast Cancer: Medication Use to Reduce Risk Recommendations made by the USPSTF are independent of the U.S. government. They should (...) not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Women at increased risk for breast cancer The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects. Women not at increased risk

2019 U.S. Preventive Services Task Force

35. Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy

Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy Axillary radiotherapy - Health Technology Wales > Axillary radiotherapy Axillary radiotherapy Topic Status Complete Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy. Summary This report (...) was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER030 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services

2019 Health Technology Wales

36. Internal mammary node irradiation for people with high-risk early breast cancer

Internal mammary node irradiation for people with high-risk early breast cancer Internal mammary node irradiation - Health Technology Wales > Internal mammary node irradiation Internal mammary node irradiation Topic Status Complete Internal mammary node irradiation for people with high-risk early breast cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence (...) on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER031 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking at this document because We may like to contact

2019 Health Technology Wales

37. Partial breast irradiation for people with early breast cancer

Partial breast irradiation for people with early breast cancer Partial breast irradiation - Health Technology Wales > Partial breast irradiation Partial breast irradiation Topic Status Complete Partial breast irradiation for people with early breast cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation (...) discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER029 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking at this document because We may like to contact you by email to find out more about how you used

2019 Health Technology Wales

38. Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping

Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search The United Kingdom is leaving the European Union on 31 October 2019. Hormone (...) replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping New data have confirmed that the risk of breast cancer is increased during use of all types of HRT, except vaginal estrogens, and have also shown that an excess risk of breast cancer persists for longer after stopping HRT than previously thought. Prescribers of HRT should discuss the updated total risk with women using HRT at their next routine appointment. Published 30

Full Text available with Trip Pro

2019 MHRA Drug Safety Update

39. Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging

Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging Federal legislation proposes requiring that screening mammography reports to practitioners and women incorporate breast density information and that women with dense breasts discuss supplemental imaging with their practitioner given their increased risk of interval breast cancer. Instead of discussing supplemental imaging with all women with dense breasts, it may (...) be more efficient to identify women at high risk of advanced breast cancer who may benefit most from supplemental imaging.To identify women at high risk of advanced breast cancer to target woman-practitioner discussions about the need for supplemental imaging.This prospective cohort study assessed 638 856 women aged 40 to 74 years who had 1 693 163 screening digital mammograms taken at Breast Cancer Surveillance Consortium (BCSC) imaging facilities from January 3, 2005, to December 31, 2014. Data

2019 EvidenceUpdates

40. Clinical utility of genomic signatures in early-stage breast cancer

Clinical utility of genomic signatures in early-stage breast cancer Clinical utility of genomic signatures in early-stage breast cancer - INAHTA Brief

2019 Haute Autorite de sante